These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22871884)

  • 1. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
    Efficace F; Baccarani M; Rosti G; Cottone F; Castagnetti F; Breccia M; Alimena G; Iurlo A; Rossi AR; Pardini S; Gherlinzoni F; Salvucci M; Tiribelli M; Vignetti M; Mandelli F
    Br J Cancer; 2012 Sep; 107(6):904-9. PubMed ID: 22871884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why are patients with chronic myeloid leukaemia (non-)adherent?
    Abraham I; MacDonald K
    Br J Cancer; 2012 Sep; 107(6):901-3. PubMed ID: 22951951
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.
    Chen TC; Chen LC; Huang YB; Chang CS
    Int J Clin Pharm; 2014 Feb; 36(1):172-81. PubMed ID: 24242992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
    Chen LC; Chen TC; Huang YB; Chang CS
    Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
    Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
    J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
    Jönsson S; Olsson B; Söderberg J; Wadenvik H
    Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 9. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
    Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
    J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
    Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
    Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
    Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G;
    Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
    Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
    Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin and oral lesions associated to imatinib mesylate therapy.
    Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
    Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients.
    Marcolino MS; Boersma E; Clementino NC; Nunes Mdo C; Barbosa MM; Silva MH; Geleijnse ML; Ribeiro AL
    Hematol Oncol; 2011 Sep; 29(3):124-30. PubMed ID: 20860069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
    Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
    MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
    Lokeshwar N; Kumar L; Kumari M
    Leuk Lymphoma; 2005 May; 46(5):781-4. PubMed ID: 16019519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.